Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 6;209(1):90–98. doi: 10.1093/cei/uxac042

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2: — Correlation between T-cell responses to SARS-CoV-2 spike and structural proteins measured by in-house PITCH ELISpot and OI T-SPOT assay. (A–C) Correlation between T-cell responses to SARS-CoV-2 spike protein measured at 1 dose + 10 weeks timepoint by three different panels: PITCH total spike, Oxford Immunotec Panel 1 + 2 and Oxford Immunotec Panel 14. n = 55 (n = 41 naïve, n = 14 previously infected). (A) Correlation between PITCH total spike and Oxford Immunotec Panel 14 at 1 dose + 10 weeks, with low responders (≤250 SFC/10⁶ PBMC) delineated by a dotted-line in the graph on the left and represented in the graph on the right (n = 45 total; n = 37 naïve and n = 8 previously-infected). (B) Correlation between PITCH total spike and Oxford Immunotec Panel 1 + 2 at 1 dose + 10 weeks, with low responders (≤250 SFC/10⁶ PBMC) delineated by a dotted-line in the graph on the left and represented in the graph on the right (n = 46 total; n = 38 naïve and n = 8 previously-infected). (C) Correlation between Oxford Immunotec Panel 1 + 2 and Panel 14 at 1 dose + 10 weeks, with low responders (≤250 SFC/10⁶ PBMC) delineated by a dotted-line in the graph on the left and represented in the graph on the right (n = 51 total; n = 39 naïve, n = 12 previously-infected). (D) Correlation between T-cell responses to SARS-CoV-2 membrane and nucleocapsid (M + NP) protein at 1 dose + 10 weeks timepoint measured by PITCH ELISpot and Oxford Immunotec T-SPOT. n = 55 (n = 41 naïve, n = 14 previously infected). (E–G) Correlation between T-cell responses to SARS-CoV-2 spike protein measured at 2 doses + 4 weeks timepoint by three different panels: PITCH total spike, Oxford Immunotec Panel 1 + 2 and Oxford Immunotec Panel 14. n = 99 (n = 75 naïve, n = 24 previously infected). (E) Correlation between PITCH total spike and Oxford Immunotec Panel 14 at 2 doses + 4 weeks, with low responders (≤250 SFC/10⁶ PBMC) delineated by a dotted-line in the graph on the left and represented in the graph on the right (n = 60 total; n = 49 naïve and n = 11 previously infected). (F) Correlation between PITCH total spike and Oxford Immunotec Panel 1 + 2 at 2 doses + 4 weeks, with low responders (≤250 SFC/10⁶ PBMC) delineated by a dotted-line in the graph on the left and represented in the graph on the right (n = 60 total; n = 49 naïve and n = 11 previously infected). (G) Correlation between Oxford Immunotec Panel 1 + 2 and Panel 14 at 2 doses + 4 weeks, with low responders (≤250 SFC/10⁶ PBMC) delineated by a dotted-line in the graph on the left and represented in the graph on the right (n = 87 total; n = 66 naïve, n = 21 previously infected). (H) Correlation between T-cell responses to SARS-CoV-2 membrane and nucleocapsid (M + NP) protein at 2 doses + 4 weeks timepoint measured by PITCH ELISpot and Oxford Immunotec T-SPOT. n = 99 (n = 75 naïve, n = 24 previously infected). (A–H) Spearman’s r correlation was performed and two-tailed P values reported (α = 0.05). Infection status at time of first vaccine, as defined by available PCR and serology data: grey symbols = naïve HCWs and red symbols = HCWs previously infected with SARS-CoV-2.